Eli Lilly & Co. closed $63.38 below its 52-week high ($972.53), which the company reached on August 22nd.

U.K. regulators will reportedly recommend the NHS not cover Eli Lilly’s (LLY) donanemab for the treatment of early ...

Britain's National Health Service (NHS) will block Eli Lilly's Alzheimer's drug donanemab on Wednesday, deeming it too ...

Eli Lilly sued three medical spas and online vendors for selling products that claim to contain the ingredient in its ...

Spirit Airlines (SAVE) extends its debt refinancing deadline with the US Bank National Association, sending the stock soaring ...

U.S. pharmaceutical giant Eli Lilly is exploring whether obesity drugs could be used to curb joblessness after signing a ...

Pharmaceutical powerhouse Eli Lilly (NYSE: LLY) is having a terrific 2024. Shares have gained 58% so far this year, handily ...

Led by Sen. Dick Durbin of Illinois, senators question if direct-to-consumer website telehealth deals are a new way around ...

Eli Lilly's valuation could look much more modest in the future, as its earnings should continue to grow at a high rate.

Eli Lilly sues vendors for selling unauthorized tirzepatide amid resolved shortages. Lawsuits target vendors offering ...

Mangoceuticals (MGRX) learned earlier this morning that Eli Lilly (LLY) has made certain public claims alleging, and has stated that it ...

Despite this, investors seem to have made up their one-track mind. Eli Lilly’s P/E ratio is more than double that of Novo ...